Aged Garlic Compound S1PC Boosts Muscle Strength, Targets Frailty Markers in Mice
Aged garlic extract component, S-1-propenyl-L-cysteine (S1PC), demonstrates significant improvements in muscle strength and reductions in frailty indicators in aged murine models by modulating a novel LKB1-SIRT1 pathway.
AI-assisted coverage: produced by SF News' automated newsroom from the cited sources and checked by automated attribution gates. Editorial responsibility: Lee Smith, Group CEO. How we work →
London, United Kingdom — 18 June 2026
New research identifies S-1-propenyl-L-cysteine (S1PC), a compound derived from aged garlic extract, as a promising agent for combating age-related muscle decline. Published findings indicate that S1PC enhances muscle strength and mitigates frailty markers in aged mice. The mechanism involves activating a specific LKB1-SIRT1 pathway, which subsequently increases the secretion of extracellular nicotinamide phosphoribosyltransferase (eNAMPT) from white adipose tissue. This eNAMPT then signals via the hypothalamus to influence muscle function, suggesting a systemic impact on healthy ageing.
Preliminary human data, although limited, recorded elevated circulating eNAMPT levels following a single S1PC dose in individuals with healthy fat mass. While these initial human observations align with the mechanistic insights from preclinical studies, robust clinical trials are necessary to conclusively validate S1PC's benefits for muscle strength and frailty reduction in an older adult population. This early-stage evidence underscores the potential for S1PC to become a novel functional ingredient within the healthy ageing supplement category.
Manufacturers and brand owners should note that while the murine data are compelling, the leap to human efficacy, especially concerning specific muscle strength endpoints or frank frailty intervention, requires significant investment in further clinical research. The established safety profile of aged garlic extract provides a favourable starting point, potentially shortening regulatory approval timelines compared to novel synthetic compounds, but specific claims for S1PC will demand dedicated evidence.
What this means for United Kingdom
UK supplement manufacturers face a strategic opportunity to differentiate in the crowded healthy ageing market, which is projected to grow annually by 8.5% through 2030, according to Mintel. Developing S1PC-containing formulations now could secure first-mover advantage. Procurement leads must assess supply chain stability and Minimum Order Quantities (MOQs) for high-specification aged garlic extracts. Regulatory teams should prepare for MHRA and FSA scrutiny on novel compound claims, requiring robust human clinical data for any specific muscle or anti-frailty benefits. Brand owners must plan for considerable R&D expenditure to substantiate product claims beyond general wellbeing, potentially leveraging Article 13.5 health claim applications in the future.
This research highlights a new biological pathway that could be targeted for muscle health. The focus on eNAMPT and its hypothalamic signalling route offers unique scientific underpinning for future product positioning. Given that the European market values scientifically-backed claims, particularly in premium segments, brands that can demonstrate the efficacy and the unique mechanism of S1PC will gain a competitive edge. Initial product concepts might target 'muscle vitality' or 'active ageing' before more definitive 'frailty reduction' claims can be substantiated.
For more on UK formulation and manufacturing best practice, learn more at Supplement Factory.